On August 1, 2019 the Company completed a public offering for nine million shares of common stock raising $75.1 million for a net price of $8.34 per share after underwriting discounts and offering expenses. The proceeds were deployed into additional ARM Agency Securities and used for general corporate purposes.

In January 2019, Capstead’s Board of Directors increased its 2017 common stock repurchase program authorization to $125 million, leaving a remaining repurchase program authorization of approximately $37 million. No shares were repurchased during 2019. Shares repurchased under this program, repurchase price and capital deployed, both presented including program costs were as follows for the indicated periods:

Year Ended December 31,

Net

Repurchase Price

Total Capital Deployed

2018

10,653,000

7.94

84,594,000

2017

397,000

8.71

3,460,000

During 2019, 2018 and 2017, additions to common equity capital related to equity-based awards to directors and employees totaled $2.6 million, $1.7 million and $1.1 million, respectively. See NOTE 11 for further information pertaining to long-term equity-based awards.

In 2013 Capstead completed a public offering of 6.8 million shares ($170.0 million face amount) of its 7.50% Series E Cumulative Redeemable Preferred Stock, liquidation preference of $25.00 per share. Shares of the Series E preferred stock are redeemable at the Company’s option for $25.00 per share, plus any accumulated and unpaid dividends. The Company issued no Series E preferred stock in 2019 or 2018. During 2017 the Company issued 2.1 million shares through an at-the-market continuous offering program for approximately $51.9 million (an average price, after expenses, of $24.77).